Skip to main content
Erschienen in: Annals of Behavioral Medicine 3/2012

01.06.2012 | BRIEF REPORT

History of Major Depressive Disorder Prospectively Predicts Worse Quality of Life in Women with Breast Cancer

verfasst von: Heather S. L. Jim, Ph.D., Brent J. Small, Ph.D., Susan Minton, D.O., Michael Andrykowski, Ph.D., Paul B. Jacobsen, Ph.D.

Erschienen in: Annals of Behavioral Medicine | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Data are scarce about whether past history of major depressive disorder in the absence of current depression places breast cancer patients at risk for worse quality of life.

Purpose

The current study prospectively examined quality of life during chemotherapy in breast cancer patients with a history of resolved major depressive disorder (n = 29) and no history of depression (n = 144).

Methods

Women with Stages 0–II breast cancer were assessed prior to and at the completion of chemotherapy. Major depressive disorder was assessed via structured interview and quality of life with the SF-36.

Results

Patients with past major depressive disorder displayed greater declines in physical functioning relative to patients with no history of depression (p ≤ 0.01).

Conclusions

Findings suggest that breast cancer patients with a history of resolved major depressive disorder are at increased risk for declines in physical functioning during chemotherapy relative to patients with no history of depression.
Literatur
1.
Zurück zum Zitat Oleske DM, Cobleigh MA, Phillips M, Nachman KL. Determination of factors associated with hospitalization in breast cancer survivors. Oncol Nurs Forum. 2004; 31:1081–1088.PubMedCrossRef Oleske DM, Cobleigh MA, Phillips M, Nachman KL. Determination of factors associated with hospitalization in breast cancer survivors. Oncol Nurs Forum. 2004; 31:1081–1088.PubMedCrossRef
2.
Zurück zum Zitat Bui QU, Ostir GV, Kuo YF, Freeman J, Goodwin JS. Relationship of depression to patient satisfaction: Findings from the barriers to breast cancer study. Breast Cancer Res Treat. 2005; 89: 23–28.PubMedCrossRef Bui QU, Ostir GV, Kuo YF, Freeman J, Goodwin JS. Relationship of depression to patient satisfaction: Findings from the barriers to breast cancer study. Breast Cancer Res Treat. 2005; 89: 23–28.PubMedCrossRef
3.
Zurück zum Zitat Grabsch B, Clarke DM, Love A, et al. Psychological morbidity and quality of life in women with advanced breast cancer: A cross-sectional survey. Palliat Support Care. 2006; 4: 47–56.PubMedCrossRef Grabsch B, Clarke DM, Love A, et al. Psychological morbidity and quality of life in women with advanced breast cancer: A cross-sectional survey. Palliat Support Care. 2006; 4: 47–56.PubMedCrossRef
4.
Zurück zum Zitat Frick E, Tyroller M, Panzer M. Anxiety, depression and quality of life of cancer patients undergoing radiation therapy: A cross-sectional study in a community hospital outpatient centre. Eur J Cancer Care (Engl). 2007; 16: 130–136.CrossRef Frick E, Tyroller M, Panzer M. Anxiety, depression and quality of life of cancer patients undergoing radiation therapy: A cross-sectional study in a community hospital outpatient centre. Eur J Cancer Care (Engl). 2007; 16: 130–136.CrossRef
5.
Zurück zum Zitat Goodwin JS, Zhang DD, Ostir GV. Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. J Am Geriatr Soc. 2004; 52: 106–111.PubMedCrossRef Goodwin JS, Zhang DD, Ostir GV. Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. J Am Geriatr Soc. 2004; 52: 106–111.PubMedCrossRef
6.
Zurück zum Zitat Colleoni M, Mandala M, Peruzzotti G, et al. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet. 2000; 356: 1326–1327.PubMedCrossRef Colleoni M, Mandala M, Peruzzotti G, et al. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet. 2000; 356: 1326–1327.PubMedCrossRef
7.
Zurück zum Zitat Watson M, Haviland JS, Greer S, Davidson J, Bliss JM. Influence of psychological response on survival in breast cancer: A population-based cohort study. Lancet. 1999; 354: 1331–1336.PubMedCrossRef Watson M, Haviland JS, Greer S, Davidson J, Bliss JM. Influence of psychological response on survival in breast cancer: A population-based cohort study. Lancet. 1999; 354: 1331–1336.PubMedCrossRef
8.
Zurück zum Zitat Phillips KA, Osborne RH, Giles GG, et al. Psychosocial factors and survival of young women with breast cancer: A population-based prospective cohort study. J Clin Oncol. 2008; 26: 4666–4671.PubMedCrossRef Phillips KA, Osborne RH, Giles GG, et al. Psychosocial factors and survival of young women with breast cancer: A population-based prospective cohort study. J Clin Oncol. 2008; 26: 4666–4671.PubMedCrossRef
9.
Zurück zum Zitat Watson M, Homewood J, Haviland J, Bliss JM. Influence of psychological response on breast cancer survival: 10-year follow-up of a population-based cohort. Eur J Cancer. 2005; 41: 1710–1714.PubMedCrossRef Watson M, Homewood J, Haviland J, Bliss JM. Influence of psychological response on breast cancer survival: 10-year follow-up of a population-based cohort. Eur J Cancer. 2005; 41: 1710–1714.PubMedCrossRef
11.
Zurück zum Zitat Andersen BL. Predicting sexual and psychologic morbidity and improving the quality of life for women with gynecologic cancer. Cancer. 1993; 71: 1678–1690.PubMedCrossRef Andersen BL. Predicting sexual and psychologic morbidity and improving the quality of life for women with gynecologic cancer. Cancer. 1993; 71: 1678–1690.PubMedCrossRef
12.
Zurück zum Zitat Costanzo ES, Lutgendorf SK, Mattes ML, et al. Adjusting to life after treatment: Distress and quality of life following treatment for breast cancer. Br J Cancer. 2007; 97: 1625–1631.PubMedCrossRef Costanzo ES, Lutgendorf SK, Mattes ML, et al. Adjusting to life after treatment: Distress and quality of life following treatment for breast cancer. Br J Cancer. 2007; 97: 1625–1631.PubMedCrossRef
13.
Zurück zum Zitat Kenne Sarenmalm E, Ohlen J, Oden A, Gaston-Johansson F. Experience and predictors of symptoms, distress and health-related quality of life over time in postmenopausal women with recurrent breast cancer. Psychooncology. 2008; 17: 497–505. Kenne Sarenmalm E, Ohlen J, Oden A, Gaston-Johansson F. Experience and predictors of symptoms, distress and health-related quality of life over time in postmenopausal women with recurrent breast cancer. Psychooncology. 2008; 17: 497–505.
14.
Zurück zum Zitat Okamura M, Yamawaki S, Akechi T, Taniguchi K, Uchitomi Y. Psychiatric disorders following first breast cancer recurrence: Prevalence, associated factors and relationship to quality of life. Jpn J Clin Oncol. 2005; 35: 302–309.PubMedCrossRef Okamura M, Yamawaki S, Akechi T, Taniguchi K, Uchitomi Y. Psychiatric disorders following first breast cancer recurrence: Prevalence, associated factors and relationship to quality of life. Jpn J Clin Oncol. 2005; 35: 302–309.PubMedCrossRef
15.
Zurück zum Zitat Okano Y, Okamura H, Watanabe T, et al. Mental adjustment to first recurrence and correlated factors in patients with breast cancer. Breast Cancer Res Treat. 2001; 67: 255–262.PubMedCrossRef Okano Y, Okamura H, Watanabe T, et al. Mental adjustment to first recurrence and correlated factors in patients with breast cancer. Breast Cancer Res Treat. 2001; 67: 255–262.PubMedCrossRef
16.
Zurück zum Zitat Jacobsen PB, Donovan KA, Small BJ, et al. Fatigue after treatment for early stage breast cancer: A controlled comparison. Cancer. 2007 110: 1851–1859.PubMedCrossRef Jacobsen PB, Donovan KA, Small BJ, et al. Fatigue after treatment for early stage breast cancer: A controlled comparison. Cancer. 2007 110: 1851–1859.PubMedCrossRef
17.
Zurück zum Zitat Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW. Can comorbidity be measured by questionnaire rather than medical record review? Med Care. 1996; 34: 73–84.PubMedCrossRef Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW. Can comorbidity be measured by questionnaire rather than medical record review? Med Care. 1996; 34: 73–84.PubMedCrossRef
18.
Zurück zum Zitat First MB, Gibbon M, Spitzer RL, Williams JB. User's Guide for the Structured Clinical Interview for the DSM-IV Axis I Disorders - Research Version. New York: Biometrics Research Department, New York State Psychiatric Institute, 1996. First MB, Gibbon M, Spitzer RL, Williams JB. User's Guide for the Structured Clinical Interview for the DSM-IV Axis I Disorders - Research Version. New York: Biometrics Research Department, New York State Psychiatric Institute, 1996.
19.
Zurück zum Zitat Radloff LS: The CES-D Scale. A self report depression scale for research in the general population. Appl Psychol Meas. 1977; 1: 119–135.CrossRef Radloff LS: The CES-D Scale. A self report depression scale for research in the general population. Appl Psychol Meas. 1977; 1: 119–135.CrossRef
20.
Zurück zum Zitat Beeber L, Shea J, McCorkle R. The Center for Epidemiological Studies Depression Scale as a measure of depressive symptoms in newly diagnosed patients. J Psychosoc Oncol. 1998; 16: 1–20.CrossRef Beeber L, Shea J, McCorkle R. The Center for Epidemiological Studies Depression Scale as a measure of depressive symptoms in newly diagnosed patients. J Psychosoc Oncol. 1998; 16: 1–20.CrossRef
21.
Zurück zum Zitat Hann D, Winter K, Jacobsen P. Measurement of depressive symptoms in cancer patients: Evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J Psychosom Res. 1999; 46: 437–443.PubMedCrossRef Hann D, Winter K, Jacobsen P. Measurement of depressive symptoms in cancer patients: Evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J Psychosom Res. 1999; 46: 437–443.PubMedCrossRef
22.
Zurück zum Zitat Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, 1993. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, 1993.
23.
Zurück zum Zitat Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston: The Health Institute, 1994. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston: The Health Institute, 1994.
24.
Zurück zum Zitat Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986; 51: 1173–1182.PubMedCrossRef Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986; 51: 1173–1182.PubMedCrossRef
25.
Zurück zum Zitat MacKinnon DP, Fairchild AJ, Fritz MS. Mediation analysis. Annu Rev Psychol. 2007; 58: 593–614.PubMedCrossRef MacKinnon DP, Fairchild AJ, Fritz MS. Mediation analysis. Annu Rev Psychol. 2007; 58: 593–614.PubMedCrossRef
26.
Zurück zum Zitat Sobel ME. Asymptotic confidence intervals for indirect effects in structural equation models. Sociol Methodol. 1982; 13: 290–312.CrossRef Sobel ME. Asymptotic confidence intervals for indirect effects in structural equation models. Sociol Methodol. 1982; 13: 290–312.CrossRef
27.
Zurück zum Zitat Burnam MA, Wells KB, Leake B, Landsverk J. Development of a brief screening instrument for detecting depressive disorders. Med Care. 1988; 26: 775–789.PubMedCrossRef Burnam MA, Wells KB, Leake B, Landsverk J. Development of a brief screening instrument for detecting depressive disorders. Med Care. 1988; 26: 775–789.PubMedCrossRef
28.
Zurück zum Zitat Cho HJ, Lavretsky H, Olmstead R, et al. Sleep disturbance and depression recurrence in community-dwelling older adults: A prospective study. Am J Psychiatry. 2008; 165: 1543–1550.PubMedCrossRef Cho HJ, Lavretsky H, Olmstead R, et al. Sleep disturbance and depression recurrence in community-dwelling older adults: A prospective study. Am J Psychiatry. 2008; 165: 1543–1550.PubMedCrossRef
29.
Zurück zum Zitat Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry. 2000; 157: 229–233.PubMedCrossRef Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry. 2000; 157: 229–233.PubMedCrossRef
30.
Zurück zum Zitat Cho HJ, Lavretsky H, Olmstead R, et al. Prior depression history and deterioration of physical health in community-dwelling older adults--a prospective cohort study. Am J Geriatr Psychiatry. 2010; 18: 442–451.PubMedCrossRef Cho HJ, Lavretsky H, Olmstead R, et al. Prior depression history and deterioration of physical health in community-dwelling older adults--a prospective cohort study. Am J Geriatr Psychiatry. 2010; 18: 442–451.PubMedCrossRef
31.
Zurück zum Zitat Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry. 1992; 149: 999–1010.PubMed Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry. 1992; 149: 999–1010.PubMed
32.
Zurück zum Zitat Monroe SM, Harkness KL. Life stress, the "kindling" hypothesis, and the recurrence of depression: Considerations from a life stress perspective. Psychol Rev. 2005; 112: 417–445.PubMedCrossRef Monroe SM, Harkness KL. Life stress, the "kindling" hypothesis, and the recurrence of depression: Considerations from a life stress perspective. Psychol Rev. 2005; 112: 417–445.PubMedCrossRef
33.
Zurück zum Zitat Navari RM, Brenner MC, Wilson MN. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat. 2008; 112: 197–201.PubMedCrossRef Navari RM, Brenner MC, Wilson MN. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat. 2008; 112: 197–201.PubMedCrossRef
34.
Zurück zum Zitat Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: A randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol. 2003; 21: 4635–4641.PubMedCrossRef Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: A randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol. 2003; 21: 4635–4641.PubMedCrossRef
35.
Zurück zum Zitat Roscoe JA, Morrow GR, Hickok JT, et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 2005; 89: 243–249.PubMedCrossRef Roscoe JA, Morrow GR, Hickok JT, et al. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 2005; 89: 243–249.PubMedCrossRef
36.
Zurück zum Zitat Jacobsen PB, Jim HS. Psychosocial interventions for anxiety and depression in adult cancer patients: Achievements and challenges. CA Cancer J Clin. 2008; 58: 214–230.PubMedCrossRef Jacobsen PB, Jim HS. Psychosocial interventions for anxiety and depression in adult cancer patients: Achievements and challenges. CA Cancer J Clin. 2008; 58: 214–230.PubMedCrossRef
Metadaten
Titel
History of Major Depressive Disorder Prospectively Predicts Worse Quality of Life in Women with Breast Cancer
verfasst von
Heather S. L. Jim, Ph.D.
Brent J. Small, Ph.D.
Susan Minton, D.O.
Michael Andrykowski, Ph.D.
Paul B. Jacobsen, Ph.D.
Publikationsdatum
01.06.2012
Verlag
Springer-Verlag
Erschienen in
Annals of Behavioral Medicine / Ausgabe 3/2012
Print ISSN: 0883-6612
Elektronische ISSN: 1532-4796
DOI
https://doi.org/10.1007/s12160-011-9333-6

Weitere Artikel der Ausgabe 3/2012

Annals of Behavioral Medicine 3/2012 Zur Ausgabe

Neu in den Fachgebieten Neurologie und Psychiatrie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.